Exagen Diagnostics files IPO plans; Genetic tests identifying cancer risks outpace understanding of results;

> Exagen Diagnostics has filed plans to raise up to $69 million in an initial public offering. Story

> Genetic tests that identify mutations that may point to cancer risk are outpacing the understanding of what they mean. Story (sub. req.)

> The Washington state life sciences industry has surpassed $1 billion in transactions, including going public, acquisitions and licensing deals. Story

> Researchers have developed a biosensor made from graphene that can identify biomarkers pointing to an increased risk of developing cancer. Item

> The FDA has formally announced an emergency-use authorization for an in vitro diagnostic device to detect the Ebola virus. Notice

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.